Abstract:Abstract We have developed an algorithm and implemented it in a software platform for the purpose of developing new anti-tumor drugs in the form of small molecules. In this study, we focused on generating molecules specifically for the treatment of lung cancer patients. To begin with, we employed deep learning (DL) techniques to evaluate the genes associated with poor clinical outcomes in lung cancer patients. By utilizing generative adversarial neural networks (GAN), we acquired additional patient data. The results of each experiment were presented as a list of genes ordered by their impact on the desired effect. We then intersected the lists of genes obtained from experiments with overall survival (OS) and progression-free interval (PFI) data. This allowed us to identify a set of genes whose expression was correlated with poor prognosis. In order to enhance the precision, we trained another DL model to distinguish between normal and tumor tissue based on gene expression. By doing so, we were able to identify the smaller set of genes that could be targeted. Subsequently, we developed a module that predicts the interactions between inhibitors and proteins. This involved representing protein amino acid sequences and chemical compound formulas in vector form, and a virtual screening of the Pubchem database. The implementation of the Drug-protein interactions module resulted in a dataset of 118,379 pairs, including 19,250 pairs describing compounds bound to proteins, and 99,129 precedents describing non-bound ones. DLwas applied, yielding a ROC-AUC of 0.86. Following the search for candidate molecules, we obtained 160,000 pairs with a predicted interaction probability above 0.99, as well as 2,921 pairs with probability of 1.0. Additionally, we created a DL-based module to predict the IC50 values in cell line experiments. Virtual pre-clinical trials were conducted using the selected inhibitors to identify relevant cell lines for subsequent laboratory experiments. Through this process, we obtained formulas for several molecules that demonstrated predicted binding to specific proteins. During the cell experiment emulation, our feature importance algorithm selected 129 genes. For the cell experiment emulation stage, we specifically chose interactions with a probability of at least 0.9. We prioritized molecules that acted on the minimum number of cell lines with a higher probability, thus ensuring higher specificity. Ultimately, we selected 5 small molecules as potential candidates, as well as certain cell lines for their validation. The NLP technologies utilized in this study demonstrated their effectiveness in processing tens of thousands of articles. The pipeline of methods presented in this paper lays the groundwork for automated AI-driven drug discovery. We have showcased the application of modern machine learning methods, particularly DL, as well as the methods used to prepare the initial data for the learning algorithms. The performance of these methods has been validated through cross-validation using data from publicly available sources. Citation Format: Dmitrii K Chebanov, Vsevolod A Misyurin, Nadezhda S Tatevosova. Deep learning-driven drug discovery: A breakthrough algorithm and its implication in lung cancer therapy development [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A014.

Abstract 1826: New inhibitors of oncology targets discovered using the affinity-mediated selection of DNA-encoded chemical libraries followed by machine-learning

Abstract 3091: Discovery of highly selective ligands with unique binding modes for challenging oncology targets using DNA-encoded chemical libraries

Machine learning on DNA-encoded libraries: A new paradigm for hit-finding

Abstract 6576: Discovery of potent and selective novel small molecule drugs to target estrogen receptor mutants in endocrine-resistant breast cancer

Abstract 3357: Identification and validation of novel molecular inhibitors from the DrugBank drug library

Abstract 2034: Discovery of novel therapeutic targets using 3D chromatin conformation and patient-specific gene regulatory networks

Abstract 3535: Seeking novel therapeutic targets in oncology using machine learning

Abstract 5333: Combining chemoproteomics with machine learning identifies functionally active covalent fragments for hard-to-drug cancer drivers

Abstract 4493: Protein structure inspired drug discovery

Abstract A014: Deep learning-driven drug discovery: A breakthrough algorithm and its implication in lung cancer therapy development

Abstract Wrk2-04: Virtual screening of ultra-large chemical spaces for novel chemotype discovery

Abstract 3287: Learning to target CDK4/6 inhibitor resistance via a breast cancer-specific atlas of cellular mechanisms

Abstract 5813: AI-driven identification and validation of novel synthetic lethal gene pairs through deep mining of cancer dependency data

Abstract 6085: Leveraging targeted epigenetic and genetic detection for cost-effective cancer classification

Abstract 5954: Big data-driven discovery of novel oncogenic fusion genes for anticancer therapy

Abstract 1915: A scalable pancancer antigen target discovery platform for precision oncology

Abstract 5887: Identifying new immunotherapy targets using machine learning and ex vivo validation

Abstract 3900: A high-throughput platform identifies novel drug combinations towards acute myeloid leukemia therapy

Abstract 544: Reverse engineering strategy for new targets identification

Abstract 680: Leveraging an RNA-targeting platform for the discovery of cell-active c-MYC mRNA-binding small molecules

Abstract C109: Discovery of New Natural Anti-Tumoral Compounds Using a Parallel Target- and Phenotypic-Driven Screening Approach.